Net sales and EBIT were below consensus (LSEG) in Q1.
Redeye comments on Carasent’s Q1 2024 report and its announcement of revised financial targets.
Biovica is about to implement an annual SEK 30m cost-saving program.
Redeye provides its initial take on Lifco’s Q1 2024 report, which came in broadly below our estimate...
Redeye comments on Evolution’s Q1-results which were slightly ahead of our forecasts although EBITDA...
Redeye leaves a comment following the yesterday’s press release of the preliminary outcome of Lipum’...
Redeye nudges our growth expectations for 2024e while slightly increasing costs.
Redeye initiates coverage of Oncopeptides, a commercial-stage biotech company focusing on multiple m...
Atria's Q1 EBIT came in clearly above LSEG Data & Analytics consensus despite the ongoing ramp-up of...
Solid 7% organic growth in Q1, underlying was even better Another $3m in restructuring costs reveals...
Q1e: We expect 25% ARR growth and adj. EBITDA of DKK -1.
Q1e: orders -2%, sales +1% y-o-y, adj. EBITA margin 7.
Fallande ARR med hög tillströmning av nya kunder Med efterhängande covid-effekter fortsatte ARR att ...
Q1-rapporten – svaga volymer och svårt jämförelsetal Nettoomsättningen sjönk med 32% y/y, varav 27% ...
Innofactor’s Q1 results were well in line with our expectations.
Redeye comments on the update from the type C FDA meeting.
Cibus posted Q1 net operating income of EUR 28.1m, up 2% y/y and 1% below Infront consensus.
Fine 7% Group organic growth which could have been better No news on CMS reimbursement, Guidance add...
Redeye comments on Thunderful Group ahead of its Q1 results (due 15 May).
Redeye comments on Fantasma Games ahead of its Q1 results (due on 8 May).
